Observational Study to Evaluate the Safety and Effectiveness of Adalloce in Adults with Rheumatoid Arthritis and Ankylosing Spondylitis

What this Trial Is About

Researchers are evaluating the efficacy and safety of Adalloce in adult patients diagnosed with Rheumatoid Arthritis RA or Ankylosing Spondylitis AS. This observational, prospective study aims to monitor patients who are newly prescribed Adalloce and have not previously received this medication. The study is sponsored by Yuhan Corporation and focuses on understanding how this treatment affects patients quality of life. The study includes patients scheduled to receive Adalloce based on their doctors recommendation. Participants will be observed over a period of 52 weeks to track changes in their health and well-being. There are no placebo or comparison groups, as this is an observational study monitoring the real-world use of Adalloce. During the study, participants will undergo regular assessments to measure changes in their quality of life using the EQ-5D-5L questionnaire. Researchers will collect data on how patients respond to the medication over time, including any side effects or safety concerns. The total duration of participation is one year, with evaluations conducted from the beginning through 52 weeks.

An Observational, Prospective Study to Assess the Efficacy and Safety of Adalloce in Patients With RA and AS